Citius Pharmaceuticals, Inc. (CTXR) Balance Sheet
CTXR balance sheet, FY2025
September 30, 2025 · U.S. dollars$130.9M assets = $53.4M liabilities + $77.5M equity
Both columns are drawn to the same scale: what CTXR owns equals what it owes plus shareholders’ equity. Hover a block for its value.
CTXR financial health
Descriptive bands, not a rating. Fiscal FY2025.
CTXR balance sheet trends, FY2016–FY2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $22.0MFY2016 | $130.9MFY2025 | +21.9%/yr | |
| Total liabilities | $5.2MFY2016 | $53.4MFY2025 | +29.6%/yr | |
| Shareholders’ equity | $16.8MFY2016 | $67.6MFY2025 | +16.7%/yr | |
| Cash & short-term investments | $294,351FY2016 | $4.3MFY2025 | +34.5%/yr | |
| Total debt | $672,970FY2016 | $1.8MFY2025 | +11.6%/yr | |
| Net cash (debt) | −$378,619FY2016 | $2.4MFY2025 | +$2.8M | |
| Working capital | −$4.3MFY2016 | −$17.0MFY2025 | −$12.7M | |
| Book value per share | $17.60FY2022 | $6.10FY2025 | −29.7%/yr | |
| Current ratio | 0.17FY2016 | 0.62FY2025 | +0.45 | |
| Debt / equity | 0.04FY2016 | 0.03FY2025 | −0.01 | |
| Shares outstanding | 5.8MFY2022 | 11.1MFY2025 | +23.7%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
CTXR assets
CTXR liabilities and equity
CTXR debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
CTXR balance sheet
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $4.3M | $3.3M | $26.5M | $41.7M | $70.1M | $13.9M | $7.9M | $9.2M | $3.2M | $294,351 |
| Cash & equivalents | $4.3M | $3.3M | $26.5M | $41.7M | $70.1M | $13.9M | $7.9M | $9.2M | $3.2M | $294,351 |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $818,343 | $0 | $0 |
| Inventory | $22.3M | $8.3M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $1.4M | $2.7M | $7.9M | $2.9M | $2.7M | $122,237 | $48,111 | $57,732 | $220,246 | $598,484 |
| Total current assets | $27.9M | $14.2M | $34.4M | $44.6M | $72.8M | $14.0M | $7.9M | $10.1M | $3.4M | $892,835 |
| Property, plant & equipment (net) | $818,694 | $246,247 | $455,858 | $650,174 | $829,851 | $987,781 | $590 | $1,483 | $3,236 | $3,742 |
| Goodwill & intangible assets | $102.1M | $102.1M | $68.7M | $68.7M | $68.7M | $28.7M | $21.0M | $21.0M | $21.0M | $21.0M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $38,062 | $38,062 | $38,062 | $38,062 | $38,062 | $57,093 | $57,093 | $2,167 | $2,167 | $66,968 |
| Total assets | $130.9M | $116.7M | $103.6M | $114.0M | $142.4M | $43.8M | $29.0M | $31.1M | $24.4M | $22.0M |
| Liabilities | ||||||||||
| Accounts payable | $13.7M | $4.9M | $2.9M | $1.2M | $1.3M | $1.9M | $2.7M | $1.6M | $602,431 | $909,156 |
| Short-term debt | $1.1M | $241,547 | $218,380 | $196,989 | $177,237 | $331,970 | $172,970 | $172,970 | $172,970 | $672,970 |
| Deferred revenue | — | — | — | — | — | — | — | — | — | $1.9M |
| Total current liabilities | $44.9M | $35.8M | $5.8M | $4.5M | $4.0M | $4.1M | $4.6M | $3.2M | $2.5M | $5.2M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $164,583 | $0 | $0 | $0 | $0 |
| Lease obligations | $813,273 | $262,865 | $481,245 | $678,234 | $855,471 | $1.0M | — | — | — | — |
| Other long-term liabilities | $8.5M | $6.7M | $6.4M | $6.0M | $5.7M | $5.8M | $5.0M | $1.7M | $775,401 | $1.6M |
| Total liabilities | $53.4M | $42.5M | $12.2M | $10.6M | $9.6M | $10.1M | $4.6M | $3.2M | $2.5M | $5.2M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $18,068 | $7,247 | $6,354 | $146,211 | $145,979 | $55,577 | $28,930 | $16,199 | $8,346 | $73,138 |
| Retained earnings (deficit) | −$238.8M | −$201.4M | −$162.2M | −$129.7M | −$96.0M | −$70.6M | −$55.8M | −$40.3M | −$27.7M | −$17.3M |
| Accumulated other comprehensive income | — | — | — | — | — | $0 | — | $0 | $0 | −$4,780 |
| Minority interest | $10.0M | $4.0M | $600,380 | $600,380 | $600,380 | — | — | — | — | — |
| Total shareholders' equity | $67.6M | $70.1M | $90.8M | $102.8M | $132.2M | $33.7M | $24.4M | $27.9M | $21.9M | $16.8M |
| Key figures | ||||||||||
| Total debt | $1.8M | $262,865 | $481,245 | $678,234 | $855,471 | $1.4M | $172,970 | $172,970 | $172,970 | $672,970 |
| Net cash (debt) | $2.4M | $3.0M | $26.0M | $41.0M | $69.2M | $12.5M | $7.7M | $9.0M | $3.0M | −$378,619 |
| Working capital | −$17.0M | −$21.6M | $28.6M | $40.0M | $68.8M | $9.9M | $3.3M | $6.9M | $955,189 | −$4.3M |
| Tangible book value | −$34.6M | −$32.1M | $22.1M | $34.1M | $63.4M | $4.9M | $3.4M | $6.9M | $960,592 | −$4.2M |
| Book value per share | $6.10 | $6.05 | $15.01 | $17.60 | — | — | — | — | — | — |
| Shares outstanding | 11.1M | 11.6M | 6.1M | 5.8M | — | — | — | — | — | — |
| Current ratio | 0.62 | 0.40 | 5.95 | 9.84 | 18.28 | 3.41 | 1.72 | 3.16 | 1.39 | 0.17 |
| Quick ratio | 0.09 | 0.09 | 4.58 | 9.21 | 17.60 | 3.38 | 1.71 | 3.14 | 1.30 | 0.06 |
| Debt / equity | 0.03 | 0.00 | 0.01 | 0.01 | 0.01 | 0.04 | 0.01 | 0.01 | 0.01 | 0.04 |
| Equity / assets | 51.6% | 60.1% | 87.7% | 90.2% | 92.8% | 76.9% | 84.1% | 89.7% | 89.9% | 76.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $17.0M | $4.6M | $7.7M | $4.3M | $6.1M | $26,410 | $1.1M | $3.3M | $17.9M | $12.6M | $20.3M | $26.5M |
| Cash & equivalents | $17.0M | $4.6M | $7.7M | $4.3M | $6.1M | $26,410 | $1.1M | $3.3M | $17.9M | $12.6M | $20.3M | $26.5M |
| Receivables | $686,235 | $1.1M | $4.0M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $22.6M | $22.7M | $22.6M | $22.3M | $17.2M | $15.3M | $14.4M | $8.3M | $0 | $0 | $0 | $0 |
| Other current assets | $3.0M | $3.4M | $3.5M | $1.4M | $1.3M | $3.0M | $2.8M | $2.7M | $10.1M | $9.0M | $7.9M | $7.9M |
| Total current assets | $43.3M | $31.7M | $37.9M | $27.9M | $24.6M | $18.4M | $18.3M | $14.2M | $28.0M | $21.6M | $28.2M | $34.4M |
| Property, plant & equipment (net) | $753,039 | $794,518 | $835,177 | $818,694 | $880,732 | $922,099 | $191,412 | $246,247 | $299,932 | $352,780 | $404,850 | $455,858 |
| Goodwill & intangible assets | $98.1M | $99.9M | $101.6M | $102.1M | $102.1M | $102.1M | $102.1M | $102.1M | $68.7M | $68.7M | $68.7M | $68.7M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $38,062 | $207,314 | $38,062 | $38,062 | $38,062 | $38,062 | $38,062 | $38,062 | $38,062 | $38,062 | $38,062 | $38,062 |
| Total assets | $142.3M | $132.5M | $140.4M | $130.9M | $127.7M | $121.5M | $120.7M | $116.7M | $97.1M | $90.7M | $97.4M | $103.6M |
| Liabilities | ||||||||||||
| Accounts payable | $8.0M | $9.5M | $11.0M | $13.7M | $10.1M | $9.4M | $7.4M | $4.9M | $1.7M | $2.7M | $2.6M | $2.9M |
| Short-term debt | $176,170 | $171,495 | $1.1M | $1.1M | $1.1M | $145,098 | $204,569 | $241,547 | $235,581 | $229,733 | $224,000 | $218,380 |
| Total current liabilities | $51.6M | $55.0M | $38.2M | $44.9M | $51.8M | $49.9M | $44.8M | $35.8M | $4.2M | $4.2M | $5.6M | $5.8M |
| Long-term debt | $6.4M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $766,957 | $808,162 | $829,646 | $813,273 | $881,651 | $931,795 | $204,569 | $262,865 | $320,011 | $374,831 | $428,569 | $481,245 |
| Other long-term liabilities | $8.3M | $8.4M | $8.7M | $8.5M | $8.3M | $8.0M | $7.0M | $6.7M | $6.7M | $6.6M | $6.5M | $6.4M |
| Total liabilities | $66.3M | $63.5M | $46.9M | $53.4M | $60.1M | $57.9M | $51.8M | $42.5M | $10.8M | $10.7M | $12.1M | $12.2M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $27,452 | $22,376 | $22,376 | $18,068 | $14,475 | $8,761 | $7,727 | $7,247 | $180,725 | $159,095 | $158,967 | $6,354 |
| Retained earnings (deficit) | −$277.1M | −$268.3M | −$247.0M | −$238.8M | −$230.8M | −$222.1M | −$211.1M | −$201.4M | −$190.6M | −$180.0M | −$171.5M | −$162.2M |
| Accumulated other comprehensive income | — | — | — | — | — | — | — | — | $0 | $0 | — | — |
| Minority interest | $9.3M | $7.5M | $13.5M | $10.0M | $2.5M | — | — | — | — | — | — | — |
| Total shareholders' equity | $66.6M | $61.5M | $80.0M | $67.6M | $65.1M | $60.7M | $65.4M | $70.1M | $85.7M | $79.4M | $84.7M | $90.8M |
| Key figures | ||||||||||||
| Total debt | $7.2M | $808,162 | $1.8M | $1.8M | $1.9M | $931,795 | $204,569 | $262,865 | $320,011 | $374,831 | $428,569 | $481,245 |
| Net cash (debt) | $9.8M | $3.8M | $5.9M | $2.4M | $4.2M | −$905,385 | $895,510 | $3.0M | $17.6M | $12.2M | $19.9M | $26.0M |
| Working capital | −$8.3M | −$23.3M | −$261,987 | −$17.0M | −$27.2M | −$31.5M | −$26.5M | −$21.6M | $23.9M | $17.4M | $22.6M | $28.6M |
| Tangible book value | −$31.5M | −$38.3M | −$21.6M | −$34.6M | −$37.1M | −$41.5M | −$36.7M | −$32.1M | $16.9M | $10.6M | $16.0M | $22.1M |
| Book value per share | $2.55 | $2.75 | $3.72 | $3.74 | $5.91 | $5.23 | $5.64 | $6.05 | $7.39 | $7.48 | $13.33 | $8.58 |
| Shares outstanding | 26.2M | 22.4M | 21.5M | 18.1M | 11.0M | 11.6M | 11.6M | 11.6M | 11.6M | 10.6M | 6.4M | 10.6M |
| Current ratio | 0.84 | 0.58 | 0.99 | 0.62 | 0.47 | 0.37 | 0.41 | 0.40 | 6.75 | 5.17 | 5.06 | 5.95 |
| Quick ratio | 0.34 | 0.10 | 0.31 | 0.09 | 0.12 | 0.00 | 0.02 | 0.09 | 4.31 | 3.01 | 3.65 | 4.58 |
| Debt / equity | 0.11 | 0.01 | 0.02 | 0.03 | 0.03 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Equity / assets | 46.8% | 46.4% | 57.0% | 51.6% | 51.0% | 49.9% | 54.2% | 60.1% | 88.3% | 87.5% | 87.0% | 87.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed December 23, 2025); data from EODHD.
CTXR financial position
At the end of fiscal 2025 (September 30, 2025), Citius Pharmaceuticals had total assets of $130.9 million (up 12.2% from a year earlier), total liabilities of $53.4 million and shareholders' equity of $67.6 million. It held $4.3 million in cash and short-term investments against $1.8 million of debt, a net cash position of $2.4 million. Its current ratio was 0.62. In the latest quarter (ended June 30, 2026) total assets were $142.3 million and equity $66.6 million.
Related: CTXR income statement, CTXR cash flow statement, CTXR key metrics. See the CTXR stock overview for the latest quote and news.
CTXR balance sheet FAQ
What are Citius Pharmaceuticals's total assets?
Citius Pharmaceuticals reported total assets of $130.9 million at the end of fiscal 2025 (September 30, 2025), compared with $116.7 million a year earlier.
How much debt does Citius Pharmaceuticals have?
Citius Pharmaceuticals had $1.8 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.03.
How much cash does Citius Pharmaceuticals have?
Citius Pharmaceuticals held $4.3 million in cash and short-term investments at the end of fiscal 2025; with $1.8 million of debt that is net cash of $2.4 million.
What is Citius Pharmaceuticals's book value?
Citius Pharmaceuticals's shareholders' equity (book value) was $67.6 million at the end of fiscal 2025, or $6.10 per share.
What is Citius Pharmaceuticals's current ratio?
Citius Pharmaceuticals had current assets of $27.9 million and current liabilities of $44.9 million, a current ratio of 0.62 (current liabilities exceed current assets).
How much goodwill does Citius Pharmaceuticals have?
Citius Pharmaceuticals carried $102.1 million of goodwill and intangible assets, 78.0% of total assets, at the end of fiscal 2025.